Phone:: +1 877 302 8632
Fax:: +1 888 205 9894 (Toll-free)
E-Mail:: orders@antibodies-online.com

For best experience we recommend to activate Javascript in your browser.

Solute Carrier Family 19, Member 3 (Slc19a3) (C-Term) Peptide

Slc19a3 Reactivity: Human Host: Synthetic BP, WB

Catalog No. ABIN5512660

$160.46

Plus shipping costs $50.00

100 μg

Shipping to: United States

Delivery in 11 to 17 Business Days

Quick Overview for Solute Carrier Family 19, Member 3 (Slc19a3) (C-Term) Peptide (ABIN5512660)

Target

SLC19A3 (Slc19a3) (Solute Carrier Family 19, Member 3 (Slc19a3))

Origin

Human

Source

Synthetic

Application

Blocking Peptide (BP), Western Blotting (WB)

Protein Region

C-Term

Sequence

VYGSYFAVIA GIFLMRSMYI TYSTKSQKDV QSPAPSENPD VSHPEEESNI

Characteristics

This is a synthetic peptide designed for use in combination with anti-SLC19A3 Antibody. It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
Solute Carrier Family 19, Member 3 (Slc19a3) peptide
Slc19a3 Reactivity: Mammalian Host: Synthetic BP, WB, IHC

Solute Carrier Family 19, Member 3 (Slc19a3) (Middle Region) peptide
Slc19a3 Reactivity: Human Host: Synthetic BP, WB

Application Notes

Optimal working dilution should be determined by the investigator.

Restrictions

For Research Use only
Format

Lyophilized

Reconstitution

Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.

Storage

-20 °C

Storage Comment

For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
Target

SLC19A3 (Slc19a3) (Solute Carrier Family 19, Member 3 (Slc19a3))

Background

This gene encodes a ubiquitously expressed transmembrane thiamine transporter that lacks folate transport activity. Mutations in this gene cause biotin-responsive basal ganglia disease (BBGD), a recessive disorder manifested in childhood that progresses to chronic encephalopathy, dystonia, quadriparesis, and death if untreated. Patients with BBGD have bilateral necrosis in the head of the caudate nucleus and in the putamen. Administration of high doses of biotin in the early progression of the disorder eliminates pathological symptoms while delayed treatment results in residual paraparesis, mild mental retardation, or dystonia. Administration of thiamine is ineffective in the treatment of this disorder. Experiments have failed to show that this protein can transport biotin. Mutations in this gene also cause a Wernicke's-like encephalopathy.

Alias Symbols: BBGD, THMD2, THTR2

Protein Size: 496

Gene ID

80704

NCBI Accession

NM_025243, NP_079519

UniProt

Q9BZV2

You are here: